一次情報の記録
重要提携・ライセンス契約
Dogwood Therapeutics Secures $5M Investment from CK Life Sciences to Advance Halneuron Phase 2b/3 in CINP
Dogwood Therapeuticsは、最大株主であるCK Life Sciencesの子会社から500万ドルの私募を発表しました。調達資金はCINPにおけるHalneuronの第3相準備活動に充てられ、現金残高を2027年3月まで延長します。これは、進行中の第2b相HAL-CINP試験のトップライン データ読出しに向けた進展に伴うものです。
主要事実
出典の抜粋
EX-99.1 4 dwtx-ex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities - ATLANTA, Ga., October 19, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that the Company has entered into a securities subscription agreement (the “Subscription Agreement”) for a $5 million investment from the Company’s largest shareholder , a subsidiary of CK Life Scienc